{"scope":{"layer":"brain_tumor","tissue_scope":"brain_tumor","species":"unknown","system":"unknown","evidence_level":"news_lead","importance":"","importance_reason":""},"id":"VC0181","type":"news","title":"AI Reveals Cancer Drug Combinations","authors_or_org":"Biohub","date":"2026-08-26","year":"2026","venue":"Biohub blog (organisation news)","url":"https://biohub.org/blog/cancer-drug-combinations-ai/","doi":"","pmid":"","brain_tumor_focus":"yes","tags":["news","dmg","drug-response","preclinical"],"tag_slugs":["news","dmg","drug-response","preclinical"],"tag_labels":["News","DMG","Drug response","Preclinical"],"tag_labels_zh":["新闻","弥漫性中线胶质瘤","药物反应","临床前"],"unmapped_tags":[],"one_line_summary_en":"Organisation news (not new evidence): Biohub's write-up of the Califano-group Nature Genetics study (doi:10.1038/s41588-026-02550-w) on network-based design of combination therapy against coexisting diffuse midline glioma cell states. It states that 8 of 9 drugs depleted the predicted target states in a subcutaneous mouse model, that in orthotopic models depleting one state let non-targeted states dominate, and that avapritinib plus ruxolitinib gave the largest survival gains in mice. Biohub says it is working with partners to build a clinical trial; no trial registration is given.","one_line_summary_zh":"机构新闻（并非新的证据）：Biohub 对 Califano 团队 Nature Genetics 研究（doi:10.1038/s41588-026-02550-w）的报道，该研究以网络方法设计针对弥漫性中线胶质瘤（DMG）共存细胞状态的联合疗法。报道称：皮下小鼠模型中 9 种药物有 8 种清除了预测的目标状态；原位模型中清除一种状态会使未被靶向的状态占优；阿伐替尼联合芦可替尼在小鼠中生存获益最大。Biohub 表示正与合作方筹建临床试验，但未给出试验注册信息。","verified":"yes","verification_source":"Biohub blog page fetched 2026-10-20 (title, datePublished 2026-08-26, content); underlying study Nature Genetics 2026-04-22 (doi:10.1038/s41588-026-02550-w, abstract via web search); no DMG trial registration found","page_url":"https://gliostate.com/library/VC0181/","api_url":"https://gliostate.com/api/items/VC0181.json","sameAs":["https://biohub.org/blog/cancer-drug-combinations-ai/"],"is_preprint":false,"facets":{"type":"https://gliostate.com/library/type/news/","year":"https://gliostate.com/library/year/2026/","tags":["https://gliostate.com/library/tag/news/","https://gliostate.com/library/tag/dmg/","https://gliostate.com/library/tag/drug-response/","https://gliostate.com/library/tag/preclinical/"]},"cited_by":[],"related":[{"id":"VC0183","title":"Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states","shared_tags":["dmg","drug-response","preclinical"],"page_url":"https://gliostate.com/library/VC0183/","api_url":"https://gliostate.com/api/items/VC0183.json"},{"id":"VC0158","title":"Tahoe Therapeutics, Arc Institute, and Biohub Partner to Generate the Largest Perturbation Dataset for Virtual Cell Models","shared_tags":["news","drug-response"],"page_url":"https://gliostate.com/library/VC0158/","api_url":"https://gliostate.com/api/items/VC0158.json"},{"id":"VC0172","title":"Neoplastic and non-neoplastic astrocyte states converge on mesenchymal and injury-response programs during glioblastoma recurrence","shared_tags":["preclinical"],"page_url":"https://gliostate.com/library/VC0172/","api_url":"https://gliostate.com/api/items/VC0172.json"},{"id":"VC0078","title":"Biological domain shift and statistical nesting concerns in generative AI-based spatial tumor growth prediction for pediatric diffuse midline glioma.","shared_tags":["dmg"],"page_url":"https://gliostate.com/library/VC0078/","api_url":"https://gliostate.com/api/items/VC0078.json"},{"id":"VC0077","title":"Generative AI for spatial tumor growth on MRI: a proof-of-principle study in pediatric diffuse midline glioma.","shared_tags":["dmg"],"page_url":"https://gliostate.com/library/VC0077/","api_url":"https://gliostate.com/api/items/VC0077.json"},{"id":"VC0133","title":"Anatomically aware simulation of patient-specific glioblastoma xenografts","shared_tags":["preclinical"],"page_url":"https://gliostate.com/library/VC0133/","api_url":"https://gliostate.com/api/items/VC0133.json"}]}